Skip to main content
Fig. 7 | Journal of Neuroinflammation

Fig. 7

From: Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy

Fig. 7

Systemic administration of etanercept (a non-BBB-penetrating TNF-α inhibitor) and TfRMAb-TNFR (a BBB-penetrating TNF-α inhibitor) results in a reduction in phosphorylated tau and microgliosis, and improvement in neuronal health in the PS19 mouse model of tauopathy. Etanercept treatment also reduces hyperactivity in the PS19 mice. These results support the development of biologic TNF-α inhibitors for tauopathies, including AD. Figure was prepared using BioRender.com

Back to article page